MSH3 expression status determines the responsiveness of cancer cells to the chemotherapeutic treatment with PARP inhibitors and platinum drugs

Details for Australian Patent Application No. 2011202823 (hide)

Owner Baylor Research Institute

Inventors Goel, Ajay; Boland, C. Richard; Koi, Minoru; Takahashi, Masanobu

Agent Pizzeys

Pub. Number AU-A-2011202823

Priority 61/442,192 12.02.11 US

Filing date 14 June 2011

Wipo publication date 30 August 2012

International Classifications

G01N 33/574 Investigating or analysing materials by specific methods not covered by groups - for cancer

C12Q 1/00 Measuring or testing processes involving enzymes or micro-organisms

G01N 33/50 Investigating or analysing materials by specific methods not covered by groups - Chemical analysis of biological material, e.g. blood, urine

G01N 37/00 Details not covered by any other group of this subclass

Event Publications

30 June 2011 Complete Application Filed

  Priority application(s): 61/442,192 12.02.11 US

30 August 2012 Application Open to Public Inspection

  Published as AU-A-2011202823

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2011202824-Systems and methods for detecting and geo-locating hazardous refuse

2011202822-Computerized Transaction Bargaining System And Method